RT Journal Article
SR Electronic
T1 Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.30.20086090
DO 10.1101/2020.04.30.20086090
A1 Michelena, Xabier
A1 Borrell, Helena
A1 López-Corbeto, Mireia
A1 López-Lasanta, María
A1 Moreno, Estefanía
A1 Pascual-Pastor, María
A1 Erra, Alba
A1 Serrat, Mayte
A1 Espartal, Esther
A1 Antón, Susana
A1 Añez, Gustavo Adolfo
A1 Caparrós-Ruiz, Raquel
A1 Pluma, Andrea
A1 Trallero-Araguás, Ernesto
A1 Barceló-Bru, Mireia
A1 Almirall, Miriam
A1 De Agustín, Juan José
A1 Segura, Jordi Lladós
A1 Julià, Antonio
A1 Marsal, Sara
YR 2020
UL http://medrxiv.org/content/early/2020/05/05/2020.04.30.20086090.abstract
AB OBJECTIVES To investigate the incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases receiving targeted biologic and synthetic disease modifying anti-rheumatic drugs (tDMARDs) and to explore the possible effect of these treatments in the clinical expression of COVID-19.METHODS A cross-sectional study comprising of a telephone survey and electronic health records review was performed including all adult and paediatric patients with rheumatic diseases treated with tDMARDs in a large rheumatology tertiary centre in Barcelona, Spain. Demographics, disease activity, COVID-19 related symptoms and contact history data were obtained from the start of the 2020 pandemic. Cumulative incidence of confirmed cases (SARS-CoV-2 positive PCR test) was compared to the population estimates for the same city districts from a governmental COVID-19 health database. Suspected cases were defined following WHO criteria and compared to those without compatible symptoms.RESULTS 959 patients with rheumatic diseases treated with tDMARDs were included. We identified 11 confirmed SARS-CoV-2 positive cases in the adult cohort and no confirmed positive cases in the paediatric cohort. All patients had a successful recovery and only one patient required admission in the intensive care unit. When using the same classification criteria (only COVID-19 positive cases with pneumonia), COVID-19 incidence rates of the rheumatic patient cohort were very similar to that of the general population [(0.48% (95% CI 0.09 to 8.65%)] and [0.58% (95% CI 5.62 to 5.99%)], respectively. We found significant differences in tDMARDs proportions between the suspected and non-suspected cases (p=0.002).CONCLUSION Adult and paediatric patients with rheumatic diseases on tDMARDs do not seem to present a higher risk of COVID-19 or a more severe disease outcome when compared to general population. Our exploratory analysis suggests that the proportion of COVID-19 suspected cases differs between tDMARDs.Competing Interest StatementXM received speaker fees from Novartis and Sanofi-Genzyme. HB received speaker fees from Lilly, MSD and Pfizer. RCR received speaker fees from MSD. ETA received speaker fees from Roche and Bristol-Myer-Squib outside this work. SM received speaker fees, grant and honoraria from Roche and Bristol-Myer-Squib outside this work. MLC, MLL, EM, MPP, AED, MSL, EE, SA, GAS, APS, MBB, MAB, JDD, JL and AJ have nothing to disclose.Funding StatementThis study did not receive any funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request to corresponding author.